DiscoverUrology Times PodcastsDr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Update: 2023-06-22
Share

Description

In this episode, David M. Schuster, MD, FACR, highlights the recent FDA approval of flotufolastat F 18 (POSLUMA), a PSMA-PET imaging agent in prostate cancer. Schuster is a professor of radiology and imaging sciences and the director of the division of nuclear medicine and molecular imaging at Emory University School of Medicine in Atlanta, Georgia.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times